ScienceBreaking NewsBreakingLatest News
Breakthrough PTSD Treatment Achieves 68% Remission Rate in Clinical Trial
Sentiment: PositiveHigh Priority
What Happened?
A new PTSD treatment using personalized brain stimulation has received FDA clearance, showing a 68% remission rate in clinical trials. Developed by Wave Neuroscience and Texas A&M, it aims to improve care for those unresponsive to existing therapies.
Key points
- Wave Neuroscience's new treatment uses Magnetic e-Resonance Therapy (MeRT) for PTSD.
- Clinical trials showed a 52% reduction in PTSD symptoms.
- 68% of participants achieved remission from PTSD symptoms.
- MeRT combines brain activity measurements with targeted magnetic stimulation.
- The treatment is the first FDA-cleared non-medication option for PTSD.
- The FDA clearance process for MeRT was expedited due to its Breakthrough Device designation.
Key insights
- The treatment's success may encourage further research into personalized mental health therapies.
- This approach could reduce reliance on medication, addressing concerns about side effects.
- The technology may eventually be adapted for other mental health conditions, broadening its impact.
Why it matters
This treatment could provide a new, effective option for millions suffering from PTSD, particularly those who have not responded to traditional therapies.
Tags
Entities
Wave Neuroscience· OrganizationTexas A&M Health Institute of Biosciences and Technology· OrganizationFDA· OrganizationErik Won· PersonDr. Kenneth S. Ramos· PersonDr. Israel Liberzon· PersonDr. Leslie S. Prichep· Person
Source
Science Daily
